All articles by Shalini Nair

  1. Top ten healthcare sector M&A financial and legal advisers for 2018

    Morgan Stanley has topped the M&A table for the top ten financial advisers in the healthcare sector for FY2018, compiled…
    Read More…

    13 Feb
  2. ALK paediatric SLIT-tablet trial meets primary endpoint

    ALK has announced positive results from a Phase III paediatric clinical trial of its sublingual allergy immunotherapy (SLIT) tablet to…
    Read More…

    16 Jan
  3. DMAb trial for Zika prevention gets FDA approval

    The Wistar Institute, Penn Medicine and Inovio Pharmaceuticals have announced the receipt of FDA approval for commencement of a first-in-human…
    Read More…

    10 Jan
  4. GenSight Biologics reports positive data from REVERSE Phase III trial

    GenSight Biologics has reported further results from its REVERSE Phase III clinical trial for the treatment of Leber hereditary optic…
    Read More…

    19 Oct
  5. Clementia completes patient enrolment in phase 3 of MOVE Trial

    Clementia Pharmaceuticals, a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders, has completed patient enrolment in the Phase…
    Read More…

    17 Aug
  6. Genentech doses first patient in Perjeta and Herceptin Phase 3 study

    Genentech has dosed the first patient in a Phase 3 study of a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab…
    Read More…

    30 Jul
  7. Ultragenyx doses first patient in DTX401 Phase 1/2 study to treat GSDIa

    Biopharmaceutical company Ultragenyx Pharmaceutical has announced dosing of the first patient in the Phase 1/2 study of DTX401, an adeno-associated…
    Read More…

    30 Jul
  8. EMA issues positive opinion on biomarker for Parkinson’s trials

    Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), along with Parkinson’s UK, has announced that the European Medicines…
    Read More…

    30 Jul
  9. Biohaven initiates Phase 2/3 clinical trial of trigriluzole

    Biohaven Pharmaceutical (Biohaven) has initiated a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients suffering…
    Read More…

    26 Jul

Go Top